Muskelskader må overvejes hos patienter, der får diffus myalgi, muskelømhed og/ eller markant forhøjet muskel CPK- værdier (> 5 gange den øvre normalgrænse); under disse tilstande skal behandlingen seponeres.
Muscle damage must be considered in any patient presenting with diffuse myalgia, muscle tenderness and/ or marked increase in muscle CPK levels (> 5x ULN); under these conditions treatment must be discontinued.